This website is intended for U.S. Healthcare Professionals.
REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
Patient Access, Reimbursement, and Co-Pay Support
Available Through
Bristol Myers Squibb is committed to helping appropriate patients initiate and maintain access to our medications during the treatment journey. That’s why we created BMS Access Support®, which offers benefit review, prior authorization assistance, and appeal process support, as well as an easy-to-initiate co-pay assistance process and information on financial support. The BMS Access Support Co-pay Assistance Program assists with out-of-pocket co-payment or co-insurance requirements for eligible, commercially insured patients who have been prescribed certain Bristol-Myers Squibb products, including REVLIMID. For more information, visit BMS Access Support, or call BMS Access Support at 1-800-861-0048,
Have Questions About Our Program or Possible Financial Support?
If you have questions about coverage for a prescribed BMS medication, BMS Access Support may be able to help. Patients and their healthcare provider can complete an enrollment form to learn about programs that may be of assistance. Visit our website or contact BMS Access Support to learn more.
